Cost Benefit Analysis of Herceptin
 

Are you worth keeping alive? I recall Lani posted something similar a few months back, but this one is a win for us:

http://www.asco.org/portal/site/ASCO...stractID=40418


Regards
Joe

This was a study done in Brazil:

Conclusion: This cost-effectiveness analysis suggests that trastuzumab in adjuvant therapy for patients with early breast cancer HER-2 positive brings important clinical benefits and in addition is a cost-effective alternative in Brazil.